Drug discovery and development – Page 5
-
Business
Protective treatment for Covid-19 makes minimal impact
Limited uptake of antibody combination for vulnerable patients, while demand for antivirals seems to be slowing
-
Opinion
Why AlphaFold won’t revolutionise drug discovery
Protein structure prediction is a hard problem, but even harder ones remain
-
Research
Teixobactin’s two pronged antibiotic attack mechanism revealed
Understanding of formation of deadly supramolecular structures could help build improved antimicrobials
-
Opinion
May cause side effects
The dose makes the poison, but understanding unwanted drug interactions is complicated
-
Research
Antigen-carrying adjuvants activate both adaptive and innate immunity
Aluminosilicate nanoparticles promote ion perturbation, pyroptosis and enhanced immunity in a cancer model
-
Business
California advances plans to make its own insulin
Governor commits $100 million to develop low-cost insulin and build manufacturing facility to strengthen drug’s supply chain
-
Opinion
Alzheimer’s, amyloid and abandoned antibodies
Biogen’s aducanumab is stumbling into obscurity. Where does that leave the amyloid hypothesis?
-
Research
Molecular machine drills holes in antibiotic-resistant bacteria killing them
Bacteria aren’t able to develop resistance against nanomotor’s deadly action
-
News
New questions raised over Sputnik Covid vaccine results point to fraudulent practices
Analysis comparing Sputnik results with five other Covid vaccines finds phase 3 trial outcome is highly improbable
-
Business
Soapbark branches out to fill essential role in vaccine recipes
The soapbark tree has long been used in traditional medicines, but is now coveted for some of our newest vaccines
-
Research
Light-activated cancer treatment uses tumour-targeting enzymes to cut side effects
Enzymatic activation of a photosensitive prodrug in cancerous cells shows promise in mice
-
Research
Breaking bacteria’s genetic silence to synthesise antibiotics that evade resistance
Prospecting in bacterial genomes offers hope in search for new antimicrobial drugs
-
Business
What is the future of Covid-19 pharmaceuticals?
Firms anticipate long-term markets for prevention and treatment
-
Feature
The incredible antibodies of sharks, llamas and camels
Sharks and llamas share a strange quirk of their immune systems. Hayley Bennett finds out how their ‘nanobodies’ could help us tackle Covid and a host of other diseases
-
Research
AI tool finds green ways to turn chemical waste into drugs
Circular approach for industry by-products considers environmental, economic and geographic aspects to rank predicted routes for real-world applications
-
Webinar
Speed up process development by making more from your offline and online data
Learn how the biotechnology R&D team at Clariant uses statistical modelling techniques to speed up the process development of their bio-ethanol product
-
Business
UK takes subscription approach for new antibiotics
Decoupling payment from prescriptions helps preserve last-line antibiotics and encourage R&D
-
News
UK’s non-profit vaccine manufacturing centre sold off before opening
Pharmaceutical firm Catalent buys government-backed facility near Oxford
-
Feature
A decade of CAR-T cell therapy
Nina Notman looks at the revolutionary treatment already taking on cancer, now aiming for wider use
-
News
Drug discovery AI that developed new nerve agents raises difficult questions
Researchers shocked by how easily algorithm discovered novel poisons even deadlier than VX